- Home
- ANY vs XCUR Comparison
ANY vs XCUR Comparison
Compare ANY & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANY | XCUR |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 13.7M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANY | XCUR |
|---|---|---|
| Price | $2.12 | $1.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 614.4K | 234.6K |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,181,000.00 | N/A |
| Revenue This Year | $15.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $1.30 |
| 52 Week High | $6.20 | $9.48 |
Technical Indicators
Market Signals| Indicator | ANY | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 28.76 |
| Support Level | $1.30 | N/A |
| Resistance Level | $2.48 | $2.02 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 74.72 | 6.95 |
Price Performance
Historical ComparisonAbout ANY Sphere 3D Corp.
Sphere 3D Corp is engaged in the Bitcoin mining business. The company has established an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers. It generates revenue from mining and selling Bitcoin.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.